INTRODUCTION {#s1}
============

Taurine up-regulated gene 1 (TUG1) is a newly identified lncRNA, located at chromosome 22q12 with a length of about 7.1kb. It was first reported as a gene up-regulated by taurine in the development of mouse retinal cells \[[@R1]\]. The lncRNA TUG1 also was found that involved in regulating mitochondrial bioenergetics by affected the expression of PGC-1α in diabetic nephropathy \[[@R2]\]. Furthermore, previously study has showed that decreased lncRNA TUG1 expression promoted mouse pancreatic β cells apoptosis and reduced insulin secretion \[[@R3]\]. In addition, up-regulated TUG1 prevent mouse livers from cold induced damage by suppressing cell apoptosis and inflammation \[[@R4]\]. Together, these results indicate that lncRNA TUG1 plays an important role in regulating the development of multiple normal biological processes.

Similarly, numerous studies have reported that TUG1 contribute to proliferation and apoptosis in a variety of tumor cells \[[@R5]--[@R7]\]. Increased lncRNA TUG1 expression promotes cell proliferation, metastasis and inhibits cell apoptosis to act as an oncogene in various cancers, such as breast cancer (BRC) \[[@R7]\], colorectal cancer (CRC) \[[@R8]\], ovarian cancer (OC) \[[@R9]\] and small cell lung cancer (SCLC) \[[@R10]\]. However, TUG1 as a tumor suppressor in some other tumors including non-small cell lung cancer (NSCLC) \[[@R11], [@R12]\], glioma \[[@R13]\], and urothelial carcinoma (UC) \[[@R14]\], up-regulated TUG1 inhibit cell proliferation and reduce tumorigenicity. Therefore, the role of TUG1 in the development and progression of tumours is inconsistent.

Besides, the prognostic value of TUG1 expression in cancer patients also with this same contradiction. Increased TUG1 expression in breast cancer (BRC) \[[@R7]\], bladder cancer (BC) \[[@R15]\], esophageal squamous cell carcinoma (ESCC) \[[@R16]\], muscle-invasive bladder cancer (MIBC) \[[@R17]\], osteosarcoma (OSA) \[[@R18]\], colorectal cancer (CRC) \[[@R8]\], gastric cancer (GC) \[[@R19]\], small cell lung cancer (SCLC) \[[@R10]\] or clear-cell renal cell carcinoma (ccRCC) \[[@R20]\] patients is associated with poor survival. However, in patients with non-small cell lung cancer (NSCLC) \[[@R11], [@R12]\], urothelial carcinoma (UC) \[[@R14]\] or glioma \[[@R13]\], the increased TUG1 expression is correlated with favorable survival. Thus, we performed present systematic review and meta-analysis to explore the reason for these inconsistent phenomena and investigate the clinical values of TUG1 expression level in various tumors. We mainly discussed the expression of TUG1 associate with prognosis, and metastasis of cancer patients. It aimed to more precisely assess the correlation between TUG1 expression and clinical outcome of human cancers.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

As showed in the flowchart (Figure [1](#F1){ref-type="fig"}), a total of 135 potentially relevant studies were searched from Embase, PubMed, Web of Science, and China Knowledge Resource Integrated (CNKI) databases. After excluding duplicates, 67 reports were preserved. After reviewing the title and abstracts, 44 records were removed. Subsequently, from the 23 remaining articles 8 were removed due to insufficient data. Finally, a total of 15 studies comprise 1560 patients were included in this meta-analysis \[[@R6]--[@R20]\]. Among these cancers derived from 13 tumor types: non-small cell lung cancer \[[@R11], [@R12]\], bladder cancer \[[@R15]\], muscle-invasive bladder cancer \[[@R17]\], esophageal squamous cell carcinoma \[[@R16]\], ovarian cancer \[[@R9]\], glioma \[[@R13]\], breast cancer \[[@R7]\], osteosarcoma \[[@R18]\], colorectal cancer \[[@R8]\], gastric cancer \[[@R19]\], clear-cell renal cell carcinoma \[[@R6], [@R20]\], urothelial carcinoma \[[@R14]\], and small cell lung cancer (SCLC) \[[@R10]\]. In all cases, TUG1 expression was detected by qRT-PCR.

![Flow diagram of the literature search and selection](oncotarget-08-65659-g001){#F1}

Correlation of TUG1 expression with overall survival {#s2_2}
----------------------------------------------------

The association between TUG1 expression and overall survival (OS) was detected in 12 studies including 1358 patients (Table [1](#T1){ref-type="table"}). Due to significant heterogeneity among studies (I^2^ = 75.7%, *P* \< 0.001) was observed, the random-effects model was used to pool the results. The merged HR indicated no significant relationship between TUG1 expression and OS (HR = 1.28, 95% CI: 0.96--1.69, *P =* 0.091; random-effects model) (Figure [2](#F2){ref-type="fig"}). To minimize heterogeneity among OS datasets, we performed subgroup analyses according to cancer type, region, sample size, analysis method, and expression level. As the results showed in Table [2](#T2){ref-type="table"}, the region subgroup and analysis method subgroup exhibited no association with OS, and significant heterogeneity were present. When sorting by cancer type, over-expression of TUG1 had an unfavorable prognostic value for bladder cancer (HR = 2.67, 95% CI: 1.47--4.87, *P* = 0.001) but no significant association with other tumors. When stratifying by sample size, high TUG1 expression was significantly related to poor OS in patients sample size less than 100 subgroup (HR = 2.08, 95% CI: 1.44--3.00, *P* \< 0.001 with less heterogeneity), while the sample size more than 100 subgroup exhibited no correlation (HR=1.00, 95% CI: 0.743--1.37, *P* = 0.991). When grouped according to the expression level of TUG1 in cancer patients, the pooled HRs for the increased TUG1 expression subgroup and decreased TUG1 expression subgroup were 1.91(95% CI: 1.33--2.75, *P* \< 0.001)) and 0.63 (95% CI: 0.48--0.82, *P* = 0.001 with less heterogeneity), respectively.

###### Main characteristic of the eligible studies for meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study          Region    Tumor\   Sample size   Test\     Cut-off        Outcome\   High TUG1 expression   Low TUG1 expression   Follow-up\           
                           type                   method                   measure                                                 (months)             
  -------------- --------- -------- ------------- --------- -------------- ---------- ---------------------- --------------------- ------------ ------- ----------
  Zhang 2014     China     NSCLC    192           qRT-PCR   median value   OS         NA                     NA                    NA           NA      ∼60

  Tan 2015       China     BC       54            qRT-PCR   NA             OS         NA                     NA                    NA           NA      Over 50

  Iliev 2016     Czech     MIBC     47            qRT-PCR   median value   OS         NA                     NA                    NA           NA      Over 100

  Jiang 2016     China     ESCC     218           qPCR      NA             OS         86/22                  NA                    82/27        NA      Over 60

  Kuang 2016     China     OC       62            qPCR      NA             NA         18/15                  NA                    12/17        NA      NA

  Li 2016        China     Glioma   120           qRT-PCR   mean value     OS         NA                     NA                    NA           NA      ∼60

  Lin 2016       China     NSCLC    89            qRT-PCR   NA             OS         NA                     NA                    NA           NA      ∼60

  Li T 2016      China     BRC      100           qRT-PCR   mean value     NA         29/26                  34/21                 25/20        8/37    NA

  Ma 2016        China     OSA      76            qRT-PCR   mean value     OS         NA                     NA                    NA           NA      ∼60

  Sun 2016       China     CRC      120           qRT-PCR   Five fold      OS         35/23                  18/25                 15/47        7/70    ∼60

  Zhang 2016     China     GC       100           qRT-PCR   median value   OS         30/20                  3/47                  27/23        2/48    ∼60

  Zhang M 2016   China     ccRCC    40            qRT-PCR   Two fold       NA         3/28                   NA                    1/8          NA      NA

  Droop 2017     Germany   UC       106           qRT-PCR   median value   OS         NA                     NA                    NA           NA      ∼200

  Niu 2017       China     SCLC     33            qRT-PCR   NA             OS         NA                     NA                    NA           NA      Over 30

  Wang 2017      China     ccRCC    203           qRT-PCR   NA             OS         29/71                  32/68                 13/90        15/88   Over 60
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

ESCC: esophageal squamous cell carcinoma; GC: gastric cancer; SCLC: small cell lung cancer; MIBC: muscle-invasive bladder cancer; NSCLC: non-small cell lung cancer; ccRCC: clear-cell renal cell carcinoma; CRC: colorectal cancer; OSA: osteosarcoma; UC: urothelial carcinoma; BC: bladder cancer; OC: ovarian cancer; BRC: breast cancer; OS: overall survival.

![Forest plot for the relationship between TUG1 expression levels with OS](oncotarget-08-65659-g002){#F2}

###### Main results of subgroup analyses

  Categories                   Subgroups                    Studies (*n*)       HR (95% CI)         *P*            Heterogeneity   
  ---------------------------- ---------------------------- ------------------- ------------------- -------------- --------------- -------
  All                                                       12                  1.28 (0.96, 1.69)   0.091          75.7            0.000
  Cancer type                  1)Digestive system cancers   3                   1.29 (0.92,1.81)    0.144          68.0            0.044
  Respiratory system cancers   3                            1.04 (0.49, 2.17)   0.927               71.3           0.031           
  Urinary system cancers       4                            1.71 (0.72, 4.09)   0.225               83.5           0.000           
  Others                       2                            1.14 (0.20,6.37)    0.882               91.6           0.001           
  2)NSCLC                      2                            0.70 (0.47,1.03)    0.073               0.0            0.594           
  Bladder cancer               2                            2.67(1.47, 4.87)    **0.001**           0.0            0.856           
  Others                       8                            1.28(0.92, 1.80)    0.147               77.7           0.000           
  Region                       Asia                         10                  1.32 (0.97, 1.79)   0.074          74.4            0.000
  Europe                       2                            1.20 (0.30, 4.80)   0.797               88.8           0.003           
  Sample size                  ≥ 100                        7                   1.00 (0.743 1.37)   0.991          77.4            0.000
  \< 100                       5                            2.08 (1.44, 3.00)   **\< 0.001**        32.5           0.205           
  Analysis method              Multivariate                 6                   1.38 (0.97, 1.96)   0.074          78.0            0.000
  Survival curves              6                            1.23 (0.65, 2.30)   0.526               77.1           0.001           
  Expression level             Increased in tumors          8                   1.91 (1.33, 2.75)   **\< 0.001**   75.1            0.000
  Decreased in tumors          4                            0.63(0.48, 0.82)    **0.001**           0.0            0.738           

Correlation of TUG1 expression with clinicopathological features {#s2_3}
----------------------------------------------------------------

From the pooled results (Figure [3](#F3){ref-type="fig"}, Table [3](#T3){ref-type="table"}), it found that high TUG1 expression was significantly associated with distant metastasis (DM) (OR = 4.22, 95% CI: 2.66--6.70, *P* \< 0.001) (Figure [4](#F4){ref-type="fig"}, Table [3](#T3){ref-type="table"}), and tumor differentiation (OR = 2.45, 95% CI: 1.28--4.70, *P* = 0.007) (Table [3](#T3){ref-type="table"}). However, there was no significant correlation between the high TUG1 levels and gender (OR = 1.04, 95% CI: 0.77--1.42, *P* = 0.774) or age (OR = 0.75, 95% CI: 0.51--1.10, *P* = 0.136) or lymph node metastasis (OR = 1.45, 95% CI: 0.85--2.50, *P* = 0.177) or clinical TNM stage (OR = 0.55, 95% CI: 0.17--1.81, *P* = 0.326) (Table [3](#T3){ref-type="table"}). Due perhaps to the inadequate data, we were failed to detect the association between the increased TUG1 expression and some other clinicopathological factors.

![Forest plot for the relationship between TUG1 expression levels with LNM](oncotarget-08-65659-g003){#F3}

###### Meta-analysis results of the associations of increased TUG1 expression with clinicopathological parameters

  ----------------------------------------------------------------------------------------------------------------------------
  Clinicopathological parameter                     Patients size   OR (95% CI)         *P* value      Heterogeneity   
  ------------------------------------------------- --------------- ------------------- -------------- --------------- -------
  Gender(Male vs. Female)                           952             1.00 (0.76--1.31)   0.978          0.0             0.536

  Age ( Age \> 60 vs. ≤ 60)                         422             0.75 (0.51--1.10)   0.136          0.0             0.460

  TNM stage( I/II vs. III/IV)                       602             0.55 (0.17--1.81)   0.326          91.2            0.000

  Differentiation ( Low /Undiffe vs. Middle/High)   641             2.45 (1.28--4.70)   **0.007**      70.0            0.019

  Lymph node metastasis\                            1034            1.45 (0.85--2.50)   0.177          71.6            0.001
  (Yes vs. No)                                                                                                         

  Distant metastasis\                               523             4.22 (2.66--6.70)   **\< 0.001**   42.2            0.158
  (Yes vs. No)                                                                                                         
  ----------------------------------------------------------------------------------------------------------------------------

![Forest plot for the relationship between TUG1 expression levels with DM](oncotarget-08-65659-g004){#F4}

Sensitivity analysis {#s2_4}
--------------------

A sensitivity analysis was conducted to evaluate the robustness of the summarized results, which were not significantly influenced by successively excluding each individual study from the pooled analysis. This suggested that the pooled HR of OS was robust (Figure [5](#F5){ref-type="fig"}).

![The sensibility analysis for this meta-analysis](oncotarget-08-65659-g005){#F5}

Publication bias {#s2_5}
----------------

The publication bias of this meta-analysis was assessed by Begg's funnel plot analysis. The funnel plot for the OS was asymmetric, suggesting potential publication bias (Figure [6](#F6){ref-type="fig"}). However, the Begg's test showed no severe publication bias among the included studies (*Pr* \> \|z\| = 0.150).

![Funnel plot analysis of potential publication bias for meta-analysis](oncotarget-08-65659-g006){#F6}

DISCUSSION {#s3}
==========

Malignant neoplasm is one of the prevalent and deadly diseases worldwide. Recent years, accumulating evidences reveal that aberrantly expression of lncRNAs has been linked to tumorigenesis and neoplasm progression \[[@R6], [@R7], [@R21]--[@R23]\]. Across all cancer-related lncRNAs, TUG1 was a newly identified non-protein coding RNA gene, it participates in regulating proliferation and apoptosis in a variety of tumor cells \[[@R5]--[@R9], [@R24]\]. Interestingly, previous studies have shown that TUG1 were up-regulated in BRC \[[@R7]\], CRC \[[@R8]\], OC \[[@R9]\], SCLC \[[@R10]\], OSA \[[@R18]\], GC \[[@R19]\], ESCC \[[@R16]\], ccRCC \[[@R6], [@R20]\], BC \[[@R15]\] and MIBC \[[@R17]\], and function as an oncogene, while TUG1 were down-regulated in NSCLC \[[@R11], [@R12]\], glioma \[[@R13]\] as well as UC \[[@R14]\], and function as a tumor suppressor. Due to inconsistent evidence existed about the role of TUG1 in tumorigenesis and neoplasm progression was inconsistent. It is necessary to systematically explore the relationship between TUG1 expression and cancer.

To analyze the results of previous studies evaluating the relationship of TUG1 expression with cancer prognosis, we performed this comprehensive meta-analysis. A total of 15 eligible studies, comprising 13 common cancer types, met the selection criterions. The data of each study were handled according to OS, gender, differentiation, clinical stage, LNM and DM. The results of this meta-analysis indicated that no significant association between high TUG1 expression and OS of cancers (HR = 1.28, 95% CI: 0.96--1.69, *P =* 0.091), which was consistent with similar research of Yu et al. \[[@R25]\]. We also found increased TUG1 expression may be an unfavorable prognostic factor for bladder cancer based on subgroup analysis, which was consistent with similar research of Liu et al. \[[@R26]\]. In addition, high TUG1 expression is significantly correlated with DM (OR = 4.22, 95% CI: 2.66--6.70, *P* \< 0.001) and tumor differentiation (OR=2.45, 95% CI: 1.28--4.70, *P* = 0.007). Furthermore, no significant correlations were observed between the high TUG1 expression and gender (OR = 1.04, 95% CI: 0.77--1.42, *P* = 0.774 or age (OR = 0.75, 95% CI: 0.51--1.10, *P* = 0.136) or lymph node metastasis (OR=1.45, 95% CI: 0.85--2.50, *P* = 0.177) or clinical TNM stage (OR = 0.55, 95% CI: 0.17--1.81, *P* = 0.326). However, the result of high TUG1 expression and LNM in our study was consistent with the result of Liu et al. \[[@R26]\] and contrary to Yang et al. \[[@R27]\]. To explore whether the heterogeneity affect the pooled results, we found increased TUG1 expression was positively associated with LNM (OR = 1.75, 95% CI: 1.09--2.81, *P* \< 0.001, random effects model) and advanced clinical stage (OR = 0.33, 95% CI: 0.14--0.77, *P* = 0.013) after exclude a datasets from Zhang et al. \[[@R11]\]. Nevertheless, due to the small size of the study, this conclusion should be further verified.

There are some limitations of the current study that should be considered in explaining the results of this meta-analysis. Firstly, there was statistical heterogeneity in our present study. The sources of heterogeneity were diverse, such as cancer type, sample size, the region of patients, tumor stage, cut off value, and so on. Noteworthy, the expression pattern of TUG1 were inconsistent in tumors, TUG1 were up-regulated compared to adjacent tissues in some tumors \[[@R6]--[@R10], [@R15]--[@R20]\], while TUG1 were down-regulated in some other tumors \[[@R11]--[@R14]\]. We further analysis found that high TUG1 level were positively associated with poor OS in increased TUG1 expression subgroup (HR = 1.91, 95%CI: 1.33--2.75, *P* \< 0.001), while increased TUG1 expression act as a favorable factor for OS in decreased TUG1 expression subgroup (HR = 0.63, 95%CI: 0.48--0.82, *P* = 0.001). Secondly, most of the included tumor patients from Chinese sample populations. Our results should be cautiously extended to other ethnic groups. Thirdly, some HRs and their corresponding 95%CIs were extracted from Kaplan-Meier curves, which are less reliable than those directly obtained from the primary studies. Finally, the cut-off values of increased TUG1 expression not consistent may be restricted to expand the clinical applicability.

In summary, our meta-analysis provides evidence that increased TUG1 expression is associated with poorer survival in cancer patients with high TUG1 expression but better survival in patients with low TUG1 expression. However, the results need to be confirmed by future studies with well-designed and larger-size in various tumors.

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy {#s4_1}
--------------------------

Literature about lncRNA TUG1 expression was searched in the online electronic databases PubMed, Embase, Web of Science and CNKI (up to April 25, 2017). Search keywords or their combinations were as follows: "taurine upregulated gene 1 OR TUG1" AND "cancer OR tumor OR tumour OR neoplasm OR neoplasma OR neoplasia OR carcinoma OR glioma OR angiosarcoma OR lymphoma OR melanoma OR leukemia". Only include English or Chinese articles in this study.

Study selection criteria {#s4_2}
------------------------

The inclusion criteria for present study were as follows: (1) studies researched the association between TUG1 expression and prognosis of cancer patients; (2) the expression levels of TUG1 were divided into two groups: high or low; (3) complete data were available for computation of odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI), and Kaplan-Meier curves or, if unavailable, related data obtained by contacting the corresponding authors.

The exclusion criteria for our meta-analysis include the following: (1) duplicate articles; (2) letters, case reports, expert opinions, editorials and reviews; (3) studies without available data; (4) sample cases fewer than 30; (5) non-human research.

Date extraction and quality assessment {#s4_3}
--------------------------------------

Two investigators (Na Li and Wei Li) independently using the Newcastle-Ottawa Quality Assessment Scale (NOS) to assess the quality of each include study, which were reported in previously studies \[[@R28], [@R29]\]. All included studies were considered to be of high quality based on NOS. The data from each included study were extracted and reviewed by two authors (Wei Li and Ke Shi) independently. To resolve the disagreements, a consensus was reached by another researcher (Na Li). The collected data were as follows: first author's name, publication date, study region, tumor type, tumor stage, detection method of TUG1 expression, assessment criteria for TUG1 expression, sample size, total patients number, number of patients in the high and low TUG1 level group, number of patients with LNM and DM in each group, survival data analysis, follow-up period, HR and corresponding 95% CI. If the survival data not showed in articles directly, a request was made to the corresponding authors, or using the Engauge Digitizer v.4.1 software to obtain it from the Kaplan-Meier curves as previously described \[[@R29]\].

Statistical methods {#s4_4}
-------------------

The STATA 12.0 software (Stata, College Station, Texas) was used to carry out all statistical analyses. Heterogeneity of pooled HRs or Ors among the eligible studies was judged by using the I-squared statistic; with I^2^ values \> 50% indicating that significant heterogeneity was present. A fixed effects model was used to analyze the pooled results when the included studies without significant heterogeneity (I^2^ \< 50 %). On the contrary, a random effects model was employed (I^2^ \> 50%). Sensibility analysis was executed to evaluate the robustness of the overall results. Begg's funnel plot was used to assess potential publication bias. Subgroup analysis was utilized to investigate the origin of heterogeneity. All the *P-*values less than 0.05 were regarded as statistical significance.
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